Privia Health Group (PRVA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for May 21, 2025, to be held virtually; registration required by May 20, 2025.
Proxy materials, including the notice, proxy statement, and annual report, are available online; paper copies can be requested.
Voting matters and shareholder proposals
Election of three Class III director nominees to serve until the 2028 annual meeting: Pamela Kimmet, Patricia Maryland, and Shawn Morris.
Advisory vote to approve compensation of named executive officers.
Ratification of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2025.
Board recommends voting FOR all nominees and proposals.
Board of directors and corporate governance
Three director nominees are up for election to the Board, each to serve a three-year term until 2028.
Latest events from Privia Health Group
- Revenue up 25.8% to $603.8M; Adjusted EBITDA up 36.3%; 2026 guidance reiterated.PRVA
Q1 20267 May 2026 - 2025 outperformance and 2026 guidance highlight robust growth, cash flow, and strategic expansion.PRVA
Q4 20256 Apr 2026 - Virtual meeting to elect directors, approve pay, and ratify auditor, with board support.PRVA
Proxy filing2 Apr 2026 - Proxy covers director elections, executive pay, auditor ratification, and strong ESG and governance.PRVA
Proxy filing2 Apr 2026 - Q2 2024 delivered strong growth, raised guidance, and maintained a robust cash position.PRVA
Q2 20242 Feb 2026 - Tech-enabled platform drives profitable growth and high retention in value-based care.PRVA
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - Raised 2024 guidance after strong Q3 growth, Indiana entry, and robust cash position.PRVA
Q3 202416 Jan 2026 - Record provider adds, robust cash flow, and expanding value-based care support 20%+ EBITDA growth.PRVA
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - 2024 outperformed guidance; 2025 targets further growth amid value-based care challenges.PRVA
Q4 202416 Dec 2025